Noviasky John, Pierce Deirdre P, Whalen Karen, Guharoy Roy, Hildreth Kenneth
Clinical Coordinator, Upstate University Hospital at Community General , Syracuse, New York.
Assistant Professor of Pharmacy Practice, St. John Fisher College, Wegmans School of Pharmacy , Rochester, New York.
Hosp Pharm. 2014 Jun;49(6):539-43. doi: 10.1310/hpj4906-539.
Bupivacaine liposomal injection was recently approved by the US Food and Drug Administration (FDA) as a local anesthetic for use in management of postsurgical pain in adults. When compared to placebo, bupivacaine liposomal decreases postoperative pain and opioid use. This review examines the efficacy of bupivacaine liposomal when compared to conventional bupivacaine ± epinephrine using published and unpublished data provided to the FDA by the manufacturer.
布比卡因脂质体注射液最近获得美国食品药品监督管理局（FDA）批准，作为一种局部麻醉剂用于成人术后疼痛管理。与安慰剂相比，布比卡因脂质体可减轻术后疼痛并减少阿片类药物的使用。本综述使用制造商提供给FDA的已发表和未发表数据，研究了布比卡因脂质体与传统布比卡因±肾上腺素相比的疗效。
